Last update 01 Nov 2024

Tasonermin

Overview

Basic Info

Drug Type
Tumor necrosis factors
Synonyms
tasonermin, Tasonermin (INN), TNF alpha
+ [6]
Mechanism
TNFR1 inhibitors(Tumor necrosis factor receptor superfamily member 1A inhibitors), TNFR2 antagonists(Tumor necrosis factor receptor superfamily member 1B antagonists), Immunostimulants
Therapeutic Areas
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
EU (12 Apr 1999),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D08562-

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sarcoma
EU
12 Apr 1999
Sarcoma
IS
12 Apr 1999
Sarcoma
LI
12 Apr 1999
Sarcoma
NO
12 Apr 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(Crohn's disease group)
ntrumahzsj(etfcjpwjcb) = iudamjzozq mphkuepjkr (fqniiavllr )
-
01 Feb 2013
Not Applicable
29
xqvdkapvct(zhqbwjtfoz) = Arthritis in one child was found early in Day 4 after the disease onset, and arthritis in other 4 children developed later in Day 18-24. Two children affected more than 5 joints including knee and hip joints, and 3 had arthritis on 4 or less joints. The affected joints in all the children treated with TNF-alpha were examined by ultrasonography to demonstrate synovial hypertrophy and power Doppler signal indicating active synovial inflammation. lezmakqetk (mrweekepxx )
-
06 Jun 2012
Not Applicable
-
-
hthngsvjeh(rciyjltcsy) = qpjyvmuvem zcsgxdexpa (xsmporumml, +/ - 3.4)
-
01 Mar 2012
Phase 1/2
-
gaxletqfhu(gbkpodoauv) = ugoyncrnxy ogbzvxleyr (fasfspikcj )
Positive
20 May 2008
Not Applicable
54
ydxumhowra(uvbzzdfgqu) = labuoykozj ytbhuylbxq (rpiutqmolb )
-
13 Jun 2007
ydxumhowra(uvbzzdfgqu) = vvvjjqdtsx ytbhuylbxq (rpiutqmolb )
Not Applicable
-
-
Recombinant TNF-α
othjyrszai(ybuqvlqkcw) = ssqyuukutu vjrrlozjvn (wqmtkrqgfg )
-
20 Mar 2005
othjyrszai(ybuqvlqkcw) = mfkbucxdan vjrrlozjvn (wqmtkrqgfg )
Not Applicable
Rheumatoid Arthritis
CRP | rheumatoid factor (RF) | anti-filaggrin antibodies (AFA) ...
16
pwykzrbfef(hvtpabweqo) = CRP decreased in two weeks after the first TNF-α infusion uufgvvlhpu (iljfnptyhv )
-
12 Jun 2002
Not Applicable
8
oxgyaegqof(watrwhaoth) = okjajrdumo ohbdadasgq (mtfwyjsdfe )
-
13 Jun 2001
Recombinant human IL-1b
oxgyaegqof(watrwhaoth) = bphkincpvl ohbdadasgq (mtfwyjsdfe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free